Regulatory Briefs: What's New From FDA
This article was originally published in The Gray Sheet
Executive Summary
Medtronic gets February panel date for its DIAM spine device, which would be the firm's second interspinous spacer on the market; FDA moves risk classifications forward for five device types; and the agency continues its scrutiny of direct-to-consumer genetic tests.